top of page

Biopharma Pulse - 6/27-7/1 Week in Review

Jul 1, 20222 min read

As we reach the end of June, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI. To subscribe to BPIQ companies Learn more here.




Table 1. BPIQ company weekly/monthly moves and YTD moves

Category

Weekly Move 6/27-7/1

YTD Move

All BPIQ Companies

​-0.89%

-45.82%

CAR-T Companies

​-1.71%

-53.85%

Gene Editing Companies

​-4.73%

-52.58%

XBI

-0.67%

-31.64%

See the biggest moves from last week below:

 

Don't miss upcoming catalysts.. Get our weekly Catalyst Watchlist Free!

*We never send you spam - unsubscribe anytime

 


Highlights for the week


Biggest positive move



Biggest negative move

  • #TALS -70.92% Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update



Additional weekly big moves

  • #AXSM +66.2% Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders

  • #DBTX +65.5% Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy.

  • #EPZM +55.8% Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology. source

  • #ENDP +54.1% Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants with Adhesive Capsulitis of the Shoulder. source

  • #KZR +53.8% Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis.

  • #STRO +21.5% Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs).

  • #GRAY +19.5% Graybug Announces Review of Strategic Alternatives.

  • #NVAX +10.6% Novavax Statement on Prototype Vaccine’s Broad Immune Responses and Accelerated Focus on Omicron BA.4/5 as Recommended by the FDA. source Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC.

  • #SPRO -11.7% Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application

  • #RLAY -13.3% Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event.

  • #NUVB -16% Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors.

  • #HRTX -20% Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability.

  • #AMRN -25% REDUCE-IT EXPLORATORY POST HOC BIOMARKER SUB-ANALYSIS SHOWS RELATIVELY SMALL CHANGES IN INFLAMMATORY MARKERS BETWEEN ICOSAPENT ETHYL AND PLACEBO.

  • #ICVX -27.1% Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV.

  • #CDAK -33.7% Codiak Provides Platform-Validating Clinical Update and Data from Phase 1 Trials of exoSTING™ and exoIL-12™.

  • #ALRN -40% Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer.

  • #ENOB -42.0%

  • #NMTR -42.1% 9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome.

  • #ANGN -42.9% ANGION ANNOUNCES DISCONTINUATION OF PHASE 2 TRIAL OF ANG-3070 IN PATIENTS WITH PRIMARY PROTEINURIC KIDNEY DISEASE

  • #AGRX -44.4% AGILE THERAPEUTICS ANNOUNCES PRICING OF $24 MILLION UPSIZED PUBLIC OFFERING. source





Highlights for next week



See our Big Movers post to learn about upcoming Movers throughout July and PDUFAs, after subscribing. Learn more here.



 
 

Comments

bottom of page